Disease · MONDO_0015247

opsoclonus-myoclonus syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. opsoclonus-myoclonus syndrome. Diseases, record MONDO_0015247. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015247

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: opsoclonus-myoclonus syndrome; Open Targets
Open Targets ID: MONDO_0015247; Open Targets
Other names: Ataxo-opso-myoclonus syndrome, Kinsbourne syndrome, OMS, Opsoclonus-Myoclonus-Ataxia Syndrome, POMA syndrome, dancing eye syndrome, dancing eye-dancing feet syndrome, oma syndrome, paraneoplastic opsoclonus-myoclonus, paraneoplastic opsoclonus-myoclonus-ataxia syndrome; Open Targets
MeSH: D053578; MeSH
NCI Thesaurus: C4686; NCI Thesaurus
Orphanet: ORPHA:1183; Orphanet
Highest stage of its drugs: Phase 3, for 5 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	1	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00033293	Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma	Phase 3	53	2016-10-03	Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma	CYCLOPHOSPHAMIDE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00202930	Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma	Phase 2	4	2021-01-22	Neuroblastoma, Opsoclonus-myoclonus	RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01868269	Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)	Phase 3	102		Opsoclonus Myoclonus Syndrome, Neuroblastoma	CYCLOPHOSPHAMIDE, DEXAMETHASONE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00244361	Effectiveness of Rituximab in Pediatric OMS Patients.	Phase 1/2	25		Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia	RITUXIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I (Chemotherapy, Immunoglobulin Therapy) vs Arm II (Chemotherapy, Observation): serious adverse events	1 of 26	1 of 27	53	NCT00033293	Trial comparisons
Arm I (Chemotherapy, Immunoglobulin Therapy) vs Arm II (Chemotherapy, Observation): Number of Responders	21 of 26	11 of 26	52	NCT00033293	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29376112	DERIVED	1	PubMed
21211990	DERIVED	1	PubMed
20606544	DERIVED	1	PubMed
19838774	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015247

GET https://conductscience.org/api/diseases/v1/MONDO_0015247/drugs

API reference For AI assistants